Abstract Background/Aims: Type 2 diabetes is associated with oxidative stress and DNA damage which can cause centrosome amplification. Thus, the study investigated centrosome amplification in type 2 diabetes and the underlying mechanisms. Methods: Centrosome numbers in human peripheral blood mononuclear blood cells (PBMC) from healthy subjects and patients with type 2 diabetes were compared to access the association between type 2 diabetes and centrosome amplification. Colon cancer cells were used to investigate the molecular mechanisms underlying the centrosome amplification triggered by high glucose, insulin and palmitic acid. Western blot analysis was used to quantify the level of protein and protein phosphorylation. Immunofluorescent staining was performed to detect centrosomes. ROS was quantified using flow cytometry technique. Transcriptpmic profiling was performed using Illumina HiSeq™500 platform. Results: We found that centrosome amplification was increased PBMC from the type 2 diabetic patients, which correlated with the levels of fasting blood glucose and HbA1c. High glucose, insulin and palmitic acid, alone or in combinations, induced ROS production and centrosome amplification. Together, they increased AKT activation as well as the expression, binding and centrosome translation of ROCK1 and 14-3-3σ. Results from further analyses showed that AKT-ROS-dependent upregulations of expression, binding and centrosome translocation of ROCK1 and 14-3-3σ was the molecular pathway underlying the centrosome amplification in vitro triggered by high glucose, insulin and palmitic acid. Moreover, the key in vitro molecular signalling events activated by high glucose, insulin and palmitic acid were verified in PBMC from the patients with type 2 diabetes. Conclusion: Our results show that type 2 diabetes promotes cell centrosome amplification, and suggest that the diabetic pathophysiological factors-activated AKT-ROS-dependent signalling of ROCK1 and 14-3-3σ is the underlying molecular mechanism.
Type 2 Diabetes Promotes Cell Centrosome Amplification via AKT-ROS-Dependent Signalling of ROCK1 and 14-3-3σ
Cell culture HCT116 cells were maintained in DMEM (low glucose, 5mM) supplemented with 50 U/ml penicillin, 50 g/ml streptomycin and 10% (v/v) foetal calf serum. Human primary breast epithelial cells were cultured in basal medium (PCS-600-030) with a growth kit (PCS-600-040, ATCC, Manassas, USA) according to ATCC instructions. Epithelial cells from the second passage in our lab were used in the study. In cell model studies, cells treated for 12 hours were used for ROS quantification. Cells treated for 24 hours were harvested for coimmunoprecipitation assay. Those treated for 30 hours were used for transcriptomic analysis. Cells treated for 48 hours were used for quantification of centrosome number and protein distribution in centrosomes. We performed time course assays and the time points were chosen, since these time points produced the highest level of differences for the measurements between the control and the treated samples.
Quantification of ROS
Changes in the intracellular ROS levels were determined using the 2, 7'-dichlorofluorescein (DCFH-DA, Beyotime, Shanghai, China) probe on a fluorospectrometer (SpectraMax M5, Molecular Devices, Silicon Valley USA). Cells grown in a 24-well plate were treated, washed twice with PBS, and incubated with DCFH-DA for 20 min at 37 o C. Then, the cells were harvested, washed once in PBS, and transferred to a 96-well plate.
Optical density values were obtained at an excitation wavelength of 488 nm and an emission wavelength of 525 nm. Alternatively, the ROS levels were quantified using a flow cytometer (FACSCalibur, BD, New Jersey, USA) according to the manufacturer's instructions.
Confocal microscopy
A cover slip was placed in a well of a 6-well plate. Cells were plated at a density of 50, 000 cells per well. Cells grown on the cover slips were fixed in cold methanol and acetone (1:1; v:v) for 6 min at -20°C, followed by three washes with PBS (10 min each time). Then, the cells were incubated with 0.1% Triton X-100 for 15 minutes and 3% BSA for 1 hour. The cells were incubated with a primary antibody in 3% BSA in PBS overnight at 4 °C, washed twice with PBS, and incubated with a FITC-conjugated secondary antibody in 3% BSA in 1×PBS for 1 hour at room temperature in the dark. Finally, the cells were mounted with mounting medium. Confocal microscopy was performed using the Zeiss LSM880 microscope (Oberkochen, Germany) with a 1.4 NA oil-immersion lens, and image processing was performed with Zen software (Oberkochen, Germany). One hundred cells were counted for their centrosome numbers for the percentage of centrosome amplification.
To separate peripheral blood mononuclear cells (PBMC), we loaded a 5-ml blood sample on the top of separation medium (LTS1077; TBD, Tianjin, China) in a centrifuge tube and centrifuged at 250 g for 20 min. The cells on the top were collected, washed twice in PBS, smeared onto a cover slip, and air dried for 24 hours at room temperature.
Transcriptomic profiling and bioinformatic annotation
The cells were harvested after treatment and total RNA was extracted. Two cDNA libraries (control or treatment with high glucose, insulin, and palmitic acid) were constructed using the Illumina TruSeq RNA Sample Preparation Kit (Illumina, USA) according to the manufacturer's instructions. After several steps of purification, adapter addition, and cDNA length selection, the two libraries were sequenced independently using an Illumina HiSeq™500 platform (Shanghai Personal Biotechnology Co., Shanghai, China). Pathway assignments were generated using GO (geneontology.org) and KEGG databases (www.kegg.jp).
Western blot analysis
The cells were lysed in RIPA buffer. Proteins were separated by polyacrylamide gel electrophoresis and transferred onto PVDF membrane. After blocking for 1 hour at room temperature with TBST containing 0.05% (v/v), Tween-20 and 5% (w/v) non-fat milk, the membranes were incubated with primary antibodies overnight at 4 °C, followed by washes with TBST containing 0.05% Tween-20.The membranes were then incubated with a horseradish peroxidase-conjugated secondary antibody for 1 hour at room temperature. ECL reagents (Thermo Biosciences, Massachusetts, USA) were used to visualize the protein bands which were captured on X-ray film. 
Knockdown of protein level
The pre-designed siRNA oligonucleotides (Sangon Technology, Shanghai, China) for Akt1, ROCK1 and 14-3-3σ were: GAGUUUGAGUACCUGAAGCUGUU (sense) and AACAGCUUCAGGUACUCAAACUC (antisense); UGAUCUUGUAGCUCCCGCAUGUGUC (sense) and ACUAGAACAUCGAGGGCGUACACAG (antisense); and ACCTGCTCTCAGTAGCCTA (sense) and TAGGCTACTGAGAGCAGGT (antisense), respectively. HCT116 cells (5×104 cells per well) were seeded in 6-well plates and cultured for 24 hours, and then were transfected with 200 pM siRNA oligonucleotides using Lipofectamine 2000 transfection reagent (Invitrogen, California, USA), according to the manufacturer's instructions. The total AKT protein level was evaluated by Western blot analysis 24 hours after transfection.
Statistical analysis
All the experiments including the transcriptomic profiling were performed in triplicate. The data are expressed as the mean ± SD. Student's t-test was performed to compare the difference between two groups. Multi-group comparisons were performed using one-way ANOVA analysis. Linear regression analysis was performed for correlations. The statistical analysis software package SPSS21 was employed for the statistical comparisons. A p value < 0.05 was considered statistically significant.
Results

Cell centrosome amplification is increased in patients with type 2 diabetes, which is in correlation with fasting blood glucose and HbA1c
To investigate whether centrosome amplification is associated with type 2 diabetes, first of all, we compared the extent of centrosome amplification in PBMC from 32 patients with type 2 diabetes and 12 healthy subjects. The clinical characteristics of the volunteers were summarized in Table 1 . Compared with the healthy subjects, the diabetic patients had higher body mass index, fasting blood glucose, HbA1c and triglyceride. Moreover, we compared the level of centrosome amplification between the healthy subject and diabetic patients. The images of centrosome and centrosome amplification were shown in Fig. 1A . The patients had a greater degree of cell centrosome amplification than the healthy subjects (8.7 % v.s.3.4%; p<0.01) (Fig. 1B) ; there was a 2.6-fold increase in centrosome amplification in PBMC from the patients. There was a slight but insignificant change in the number of cells with one or two centrosome. When the diabetic patients were divided into two groups according to their fasting blood glucose level less or greater than 10mM, there was a step-wise increase in centrosome amplification (p<0.01; Fig. 1C ). In the patients with fasting blood glucose greater than 10 mM, the number of cells with two centrsome was increased (p<0.05), while of number of cells with one centrosome was decreased (p<0.05), when compared with that in the healthy subjects. Indeed, in all the volunteers, correlation analysis showed that the extent of cell centrosome amplification was correlated with the fasting blood glucose level (R 2 = 0.7; p<0.01; Fig. 1D ) and HbA1c (R 2 =0.7; p<0.01; Fig. 1E ). Similarly, in the patients alone, the level of centrosome amplification was also correlated with fasting blood glucose (R 2 = 0.5; p <0.01; Fig. 1F ) and HbA1c (R 2 =0.4; p<0.01; Fig. 1G ), though to a lesser extent.
High glucose, insulin and palmitic acid, alone or in combinations, induce centrosome amplification via ROS production
We then investigated whether the pathophysiological factors in type 2 diabetes could induce centrosome amplification via specific molecular pathway using colon cancer cells as an experimental model. Some results were verified in normal human breast epithelial cells wherever it was considered to be meaningful, which was to verify findings from experiments using cancer cells in non-cancerous cell model. Palmitic acid, the most common saturated free fatty acid, was used to represent free fatty acids. We tested ROS pathway to start with. Fluorescent spectrophotometry was used to quantify the level of ROS when experiments involved more than three samples. Otherwise, flow cytometry analysis was employed. The results showed that high glucose, insulin and palmitic acid, alone or in combinations, significantly induced ROS production ( Fig. 2A ) and centrosome amplification (Fig. 2C) in the cancer cells. Amongst different treatment groups, the number of the cancer cells with one centrosome was decreased (p<0.05), while the number of those with two centrosomes remain comparable, when compared with that in the control group (p>0.05). High glucose, insulin and palmitic acid individually induced centrosome amplification in concentration-dependent manners (figures not shown). They, together, also triggered ROS production (Fig. 2B ) and centrosome amplification (Fig. 2D ) in the normal human breast epithelial cells. In the treated groups of the normal breast cells, cell numbers with two centrosomes did not change significantly. However, the cell numbers with one centrosome decreased (p<0.01), except that in the insulin-treated group. Antioxidant N-acetylcysteine (NAC) was able to inhibit the ROS production and the centrosome amplification ( Fig. 2A -2D) . By comparing the levels of centrosome amplification in different treatment groups, we found that the samples treated with high glucose, insulin and palmitic acid together had the highest level of centrosome amplification Most cells with centrosome amplification had 3-6 centroeomes in a cell.
In
F u n c t i o n a l transcriptomic analysis identifies AKT, ROCK1 and 14-3-3σ as signal mediators for the centrosome amplification
To further identify the molecular signals for the centrosome amplification, we performed a functional transcriptomic analysis between the control samples and those treated with high glucose, insulin and palmitic acid. The differentially expressed genes were summarized (for all online suppl. material, see www. karger.com/doi/10.1159/000489812 , Table S1 ). In total, 729 genes were differentially expressed, with 508 upregulated and 221 downregulated. Results of bioinformatic annotation were included (see online suppl. material) in suppl. Fig. S1-S5 . Functional enrichment using GO analysis assigned the genes to 37 terms in three categories of molecular component, molecular function and biological process (see online suppl. material, Fig. S1 ). The top terms were molecular function, cellular component, biological process and cell, which had 9%, 9%, 8.4% and 8.3% of the genes, respectively. KEGG annotation identified 37 pathways which were related to different functional groups (see online suppl. material, Fig. S2 ). The top pathways were signal transduction, infectious diseases, cancer, immune system and endocrine system, which had 15.6%, 11.6%, 11.1%, 7.4% and 7.0% of the genes, respectively. Notably, AKT (see online suppl. material, Fig. S3 ), ROCK (see online suppl. material, Fig. S4 ) and 14-3-3σ (see online suppl. material, Fig. S5 ) pathways were activated, which were chosen for further functional analysis. Western blot analyses confirmed that high glucose, insulin and palmitic acid activated AKT, which was inhibited by AKT inhibitor Ly294002 or siRNA (Fig.  3A) . Similarly, ROCK1 (Fig. 3B ) and 14-3-3σ (Fig. 3C ) protein levels were upregulated, which were inhibited their specific siRNA (Figs. 3B and 3C) . We then performed functional analyses to examine whether AKT, ROCK1 and 14-3-3σ mediated the centrosome amplification. Indeed, inhibition of AKT using chemical inhibitor or siRNA could inhibit the centrosome amplification (Fig. 3D) . Similarly, siRNA for ROCK1 (Fig. 3E) and siRNA for 14-3-3σ (Fig. 3F) were also able to inhibit the centrosome amplification. Moreover, AKT chemical inhibitor, AKT siRNA, ROCK1 siRNA and 14-3-3σsiRNA individually were all able to inhibit the cen- 
AKT-ROS-dependent signaling of ROCK1 and 14-3-3σ is the molecular pathway for the centrosome amplification
We next delineated the signal transduction pathway for the centrosome amplification in the colon cancer cells. The logic was that inhibition of an upstream signal would inhibit downstream one(s), while inhibition of a downstream signal would not affect the upstream one(s). We observed that inhibition of AKT using chemical inhibitor (Fig.  4A) or siRNA (Fig. 4B ) was able to inhibit ROS production as well as the upregulations of ROCK1 (Figs. 4C) and 14-3-3σ (Fig. 4D) . NAC was able to inhibit the upregulation of ROCK1 (Fig. 4E ) and 14-3- (Fig. 4F ), but did not affect the activation of AKT (Fig. 4G) . ROCK1 or 14-3-3σsiRNA did not affect AKT activation (Fig. 4H) or ROS production (Fig. 4I) .
High glucose, insulin and palmitic acid increase the binding between ROCK1 and 14-3-3σ as well as their centrosome translocation Next, we investigated the relationships amongst ROCK1, 14-3-3σ and centrosome in the cancer cells by using ROCK1 and 14-3-3σ antibodies to pull down their binding partners, and analyze the centrosome translocation of the two proteins. In pull-down samples using ROCK1 antibody, 14-3-3σ protein was detected, which was increased in the cells treated with high glucose, insulin and palmitic acid (Fig. 5A) . Similarly, high glucose, insulin and palmitic acid increased the pull down of ROCK1 using 14-3-3σ antibody (Fig. 5B) . AKT inhibitor and NAC were able to inhibit the increase in co-precipitation of ROCK1 and14-3-3σ from the cells treated by high glucose, insulin and palmitic acid (Figs. 5A and 5B). These observations on the Western blot analysis images were confirmed when the images were digitalized and quantified (Figs. 5C and 5D ). As shown in confocal images in Figs. 5E and 5F respectively, ROCK1 and 14-3-3σ were localized in the centrosome in all the treated samples. The fluorescent intensity of ROCK1 staining, which indicates the level of ROCK1 in the centrosomes, was higher in the treated cells compared to that in the control cells, which was inhibited by AKT inhibitor or NAC but not 14-3-3σsiRNA (Fig. 5G) . Comparing with that only 1% of the control cells had 14-3-3σ in the centrosomes, approximately 20% of the cells treated with high glucose, insulin and palmitic acid had 14-3-3σ in the centrosomes, which was inhibited by AKT inhibitor, NAC or ROCK1 siRNA (all at p< 0.01; Fig. 5H ).
The increases in AKT activation and ROS production as well as expression, binding and centrosome location of ROCK1 and 14-3-3σ in vitro are verified in the PBMC from the volunteers
Finally, we investigated whether the molecular signalling events found in vitro occurred in vivo in patients with type 2 diabetes. We compared these molecular events between the PBMC from healthy volunteers and those from type 2 diabetic patients. The results showed that PBMC from the diabetic patients had increased level of AKT activation (Fig. 6A) and ROS pro- [21] . Cancer patients with type 2 diabetes have poorer prognosis than those without diabetes [22] . However, it remains unknown why type 2 diabetes favours cancer development. Centrosome amplification can initiate or promote in different animal models [7, 15, 20] and increase cancer cell invasion potential [16] . In the present study, we showed that patients with type 2 diabetes had increased level of cell centrosome amplification by 2.6 folds (Fig. 1) . We wonder whether the type 2 diabetes-associated centrosome amplification can contribute to cancer development in type 2 diabetes. Type 2 diabetic patients present hyperglycemia, hyperinsulinemia and increased level of free fatty acid, at least per a period of time in disease development. Our results showed that the phathophysiological factors could induce centrosome amplification in colon cancer HCT 116 cell and normal human breast epithelial cells (Fig. 2) , suggesting that the pahtophysiological factors are the inducers for the centrosome amplification. It would be interesting to examine centrosome amplification in normal colon cells. However, there was no resource where we could obtain normal colon cells.
Our results (Figs. 3-6 ) support the findings that AKT [23] and ROS [17] can mediate centrosome amplification, and further place AKT upstream of ROS. In an apoptosis model, activation of ROCK1 causes AKT inactivation [24] , which is different from our results that placed ROCK1 downstream of AKT activation (Figs. 4C). Our result (Fig. 4E) showed that ROS was upstream of ROCK1, which is in agreement with the observations by Shen and Wang [25] . Oh and Jang show that AKT can be upstream of 14-3-3σ [26] , which is supported by our result (Figs. 4D) .
As shown in Fig. 4 , inhibition of AKT inhibits all other signals. Inhibition of ROS inhibits ROCK1 and 14-3-3σ but not AKT. Inhibition of ROCK1 or 14-3-3σ did not affect any other signals. This suggests that AKT-ROS-dependent signalling of ROCK1 and 14-3-3σ is the pathway underlying the centrosome amplification by the experimental treatment. In most cases, 14-3-3σ was clearly detected in the centrosomes in the treated cells (Fig. 5F ). In the control cells with duplicated centrosome, 14-3-3σ level was low and the signal was often barely seen on photos. Knockdown of ROCK1 inhibited 14-3-3σ translocation to centrosome, while knockdown of 14-3-3σ did not affect the translocation of ROCK1 to the centrosomes (Figs. 5G and 5H), which suggests that ROCK1 transports 14-3-3σ to centrosome or is involved in 14-3-3σtranslocation to centrosome after treatment. Downregulation of either ROCK1 or 14-3-3σ inhibited the centrosome amplification (Figs. 3E and 3F ), which suggests that the integrity of ROCK1 and 14-3-3σ complex is required for the centrosome amplification. These data suggest that the pathophysiological factors of type 2 diabetes activate AKT-ROS signalling which promotes the expression and binding of ROCK1 and 14-3-3σ which then move to centrosome to promote centrosome amplification. High glucose, insulin and palmitic acid, alone or in combinations, did not affect the cell viability under the experimental conditions, with the exception that high glucose treatment increased cell viability (data not shown). In some cell line models, centrosome amplification is associated with cell cycle arrest [27] . In our study, high glucose, insulin and palmitic acid, alone or in combination, did not disturb the cell cycle (data not shown), which suggests that cell cycle arrest is not a prerequisite for the centrosome amplification under our experimental conditions. At the concentrations of 10, 20 and 30 µM, linoleic acid did not significantly affect the centrosome amplification (figure not shown), suggesting that unsaturated free fatty acids are unable to suppress the centrosome amplification.
In our study, 3.4% of the PBMC from the healthy subjects displayed centrosome amplification (Fig. 1B) , which agrees with the finding by Dementyeva and do-workers that approximately 3% of the peripheral blood cells from healthy donors display centrosome amplification [28] .
It is known that obesity increases the risk for cancer [29] . There is also evidence that type 1 diabetes modestly increases the risk for cancer [30] . Obesity is associated with increased plasma levels of insulin and free fatty acids [31] .Type 1diabetes is associated with hyperglycaemia and increased free fatty acid level. Increased free fatty acid, as palmitic acid used in the study, and high glucose alone could cause centrosome amplification (Figs. 2C-2D ). We speculate whether centrosome amplification plays a role for the increased cancer risk in obesity and type 1 diabetes. Moreover, our results (Figs. 3B and 3C) showed that the diabetic pathophysiological factors could upregulate ROCK1 and 14-3-3σ which are associated with neurodegeneration [32, 33] . Thus it would be interesting to investigate whether ROCK1 or 14-3-3σ is a link between type 2 diabetes and Alzheimer's disease which shows an increased risk in type 2 diabetes [34] .
The study involved limited number of subjects. Further analysis with large cohorts is required to confirm the findings. Moreover, studies using animal models are required to test whether normal cells with centrosome amplification triggered by the pathophysiological factors in type 2 diabetes can initiate tumorigenesis in vivo. In the study, we used PBMC to demonstrate the increase in centrosome amplification in type 2 diabetes. This raises a concern of whether centrosome amplification occurs in other tissues prone to diabetesrelated cancer.
Conclusion
Our results suggest that the pathophysiological factors in type 2 diabetes can cause centrosome amplification via AKT-ROS pathway-dependent upregulations in expression, binding and centrosome translocation of ROCK1 and 14-3-3σ, which leads to increase in cell centrosome amplification in type 2 diabetes.
